Your Q Morning Crew
    5:00 a.m. - 11:00 a.m.
  • Listen Live

  • Join The Q Crew

  • TikTok

  • X

  • Instagram

  • Facebook

  • Mobile Apps

  • Home
  • Shows
    • Your Q Morning Crew
      • What You Missed
      • QDR Hometown Hero
    • Abby Leigh
      • Fursdays
    • Mad Dawg
    • Steve Maher
    • PineCone Bluegrass Show
    • QDR Homegrown Country
    • Country Countdown USA
  • Contests
    • View All Contests
    • Contest Rules
  • Features
    • Advice
    • Coupons
    • Crossword Puzzle
    • Daily Comic Strips
    • Fursdays
    • Gold Star Teacher of the Month
    • Horoscopes
    • Interviews
      • Exclusive Live Performances
    • News, Sports and Weather
    • Pet Adoption
    • QDR Hometown Hero
    • Live and Kickin’ Fridays
    • Recipes
    • Slideshows
    • Sudoku
  • Events
    • Station Events and Concerts
    • Community Events
    • Submit Your Community Event
    • Photos
  • Connect
    • Contact/Directions
    • 94.7 QDR App
    • Join The Q Crew
    • Advertise
    • Social Media
      • Facebook
      • Twitter
      • Instagram
      • YouTube
      • TikTok
  • search
FDA approves Moderna’s new lower-dose COVID-19 vaccine

A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Photo by Sarah Silbiger/Getty Images)

FDA approves Moderna’s new lower-dose COVID-19 vaccine

The U.S. approved a new COVID-19 vaccine made by Moderna late Friday but with limits on who can use it — not a replacement for the company’s existing shot, but a second option.

The new vaccine, mNexspike, is a step toward next-generation coronavirus vaccines. It’s made in a way that allows for a lower dose — a fifth of the dose of its current COVID-19 vaccine, Spikevax — by refining its immune target.

The approval “adds an important new tool to help protect people at high risk of severe disease from COVID-19,” Stephane Bancel, Moderna’s CEO, said in a statement Saturday.

The Food and Drug Administration approved the new vaccine for use in all adults 65 and older, and for people age 12 to 64 who have a least one health condition that puts them at increased risk from the coronavirus.

That’s the same limit that the FDA set in licensing another COVID-19 vaccine option from competitor Novavax.

Those restrictions are a departure from how the U.S. has handled COVID-19 vaccines until now, reflecting skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump officials.

Moderna’s existing vaccine doesn’t face those limits and has long been used for anyone ages 6 months and older. The company said it expected to offer both options this fall.

The FDA’s approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna’s existing vaccine. It found the new vaccine was safe and was at least as effective — and more by some measures — than the original shot, the company said.

The news came just days after the Trump administration canceled funding for Moderna to develop a vaccine against potential pandemic flu viruses, including the H5N1 bird flu, despite promising early study results.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Recent News

Hometown Hero of the Week: Brittany Mitchell, June 4th, 2025

Gold Star Teacher of the Month: June 2025 – Nell “Nellie” Rushton

Hometown Hero of the Week: William Taylor, May 28th, 2025

Fursday: Meet Guthrie from APS of Durham!

Hometown Hero of the Week: Kendall Marley, May 21st, 2025

Meet Illicium: A Shade-Loving Shrub with Personality

Fursday: Meet Delphi from Second Chance!

Hometown Hero of the Week: Brad Boswell, May 14th, 2025

Fursday: Meet Dutch from APS of Durham!

Hometown Hero of the Week: Bruce Rose, May 7th, 2025

  • La Ley 101.1FM

Copyright © 2025 WQDR-FM. All Rights Reserved.

View Full Site

  • Advertise
  • Contest Rules
  • Privacy Policy
  • Terms of Service
  • Employment Opportunities
  • Public Inspection File
  • FCC Applications
  • EEO
Powered By SoCast